These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34774360)

  • 1. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    McLean HQ; Levine MZ; King JP; Flannery B; Belongia EA
    Vaccine; 2021 Dec; 39(49):7146-7152. PubMed ID: 34774360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.
    Cowling BJ; Perera RAPM; Valkenburg SA; Leung NHL; Iuliano AD; Tam YH; Wong JHF; Fang VJ; Li APY; So HC; Ip DKM; Azziz-Baumgartner E; Fry AM; Levine MZ; Gangappa S; Sambhara S; Barr IG; Skowronski DM; Peiris JSM; Thompson MG
    Clin Infect Dis; 2020 Oct; 71(7):1704-1714. PubMed ID: 31828291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.
    Dawood FS; Naleway AL; Flannery B; Levine MZ; Murthy K; Sambhara S; Gangappa S; Edwards L; Ball S; Grant L; Belongia E; Bounds K; Cao W; Gross FL; Groom H; Fry AM; Rentz Hunt D; Jeddy Z; Mishina M; Kim SS; Wesley MG; Spencer S; Thompson MG; Gaglani M
    Clin Infect Dis; 2021 Dec; 73(11):1973-1981. PubMed ID: 34245243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.
    Moehling KK; Zimmerman RK; Nowalk MP; Jeng Lin C; Martin JM; Alcorn JF; Susick M; Burroughs A; Holiday C; Flannery B; Levine MZ
    Vaccine; 2020 Jul; 38(33):5171-5177. PubMed ID: 32580919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
    Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
    Thomas LD; Batarseh E; Hamdan L; Haddadin Z; Dulek D; Kalams S; Stewart LS; Stahl AL; Rahman H; Amarin JZ; Hayek H; Ison M; Overton ET; Pergam SA; Spieker AJ; Halasa NB;
    Clin Infect Dis; 2023 Dec; 77(12):1723-1732. PubMed ID: 39219510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).
    Kase T; Inoue M; Morikawa S; Kumashiro H; Hiroi S; Nakata K; Ito K; Ishibashi M; Tsuru T; Irie S; Maeda A; Ohfuji S; Fukushima W; Hirota Y
    Vaccine; 2020 Sep; 38(42):6524-6532. PubMed ID: 32873406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016.
    McLean HQ; King JP; Talley P; Flannery B; Spencer S; Levine MZ; Friedrich TC; Belongia EA
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):173-180. PubMed ID: 30759228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial.
    Schuster JE; Hamdan L; Dulek DE; Kitko CL; Batarseh E; Haddadin Z; Stewart LS; Stahl A; Potter M; Rahman H; Kalams SA; Bocchini CE; Moulton EA; Coffin SE; Ardura MI; Wattier RL; Maron G; Grimley M; Paulsen G; Harrison CJ; Freedman JL; Carpenter PA; Englund JA; Munoz FM; Danziger-Isakov L; Spieker AJ; Halasa NB;
    Clin Infect Dis; 2024 Jan; 78(1):217-226. PubMed ID: 37800415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza A(H3N2) Antibody Responses to Standard-Dose Versus Enhanced Influenza Vaccine Immunogenicity in Older Adults and Prior Season's Vaccine Status.
    Zhong S; Ng TWY; Skowronski DM; Iuliano AD; Leung NHL; Perera RAPM; Ho F; Fang VJ; Tam YH; Ip DKM; Havers FG; Fry AM; Aziz-Baumgartner E; Barr IG; Peiris M; Thompson MG; Cowling BJ
    J Infect Dis; 2024 May; 229(5):1451-1459. PubMed ID: 37950884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
    Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
    Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults.
    Boyce TG; Levine MZ; McClure DL; King JP; Flannery B; Nguyen HQ; Belongia EA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2370087. PubMed ID: 38982712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
    PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.